TherapeuticsMD, Inc. Announces Plans in Hormone Therapy That Concur With the Recent Joint Statement from NAMS, ASRM and The Endocrine Society

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD™, Inc. [OTCQB: TXMD], parent company of vitaMedMD®, LLC (“vitaMedMD”), a specialty pharmaceutical company (“TherapeuticsMD” or the “Company”), announced today its plans to file up to three Investigational New Drug applications (“INDs”) with the U.S. Food and Drug Administration (“FDA”) this year and if accepted, will initiate Phase III clinical trials in the field of hormone therapy for menopausal women. During the same time period, the Company expects to file additional patents for these products.